TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No change in prescribed antihypertension medications within the previous 30 days~* Study staff able to visualize and measure the brachial artery diameter by high resolution vascular ultrasound required for FMD measurements~* ISH with the following mean seated BP: SBP \> 145 and \< 180 mmHg. Diastolic blood pressure \< 90mmHg~Exclusion Criteria:~* Has known hypersensitivity to 6RBH4 or its excipients~* Pregnant or breastfeeding at screening~* Use of any investigational product or investigational medical device within 30 days prior to screening~* Current disease or condition that would interfere with study participation or safety such as the following: heart failure, atrial fibrillation, aortic valve disease, bleeding disorders, history of repeated syncope or vertigo, severe GERD, GI ulcer, symptomatic coronary or peripheral vascular disease, arrhythmia, serious neurologic disorders including seizures, organ transplant or organ failure~* Hypertension secondary to other medical conditions~* Any severe comorbid condition that would limit life expectancy to \<6 months~* Current use of any nicotine containing substances~* History of drug or alcohol abuse~* MI, stroke or surgery within 90 days before Screening Visit~* CABG within 6 months before the Screening Visit~* Serum creatinine \>2.0mg/dl or AST, ALT, GGT levels \>2times upper limit of normal~* Concomitant treatment with: any drug known to inhibit folate metabolism, any phosphodiesterase-5 or -3 inhibitor~* Previous treatment with any formulation of BH4

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Drug (Type: EXPERIMENTAL): None
- Placebo Comparator (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Belatacept for Renal Transplant Recipients With Delayed Graft Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed Written Informed Consent~2. Deceased donor renal transplant recipient~3. Men and women, aged 18-60 years of age~Exclusion Criteria:~1. Seronegative or unknown EBV serostatus~2. Patients unwilling or incapable of providing informed consent.~3. Patients with active tuberculosis or positive TB test without evidence of infection treatment.~4. Patients with demonstrated acute rejection on first biopsy evaluation for delayed graft function; Second transplant or multiple organ transplant; patients more than 12 days post renal transplant prior to enrollment~5. Evidence of Sepsis or other clinical indicators deemed clinically contraindicated for study enrollment by the primary physician~6. Inadequate vein access to receive monthly IV infusions~7. Prior proven allergy or severe adverse drug reaction to mycophenolate, steroid or Belatacept preventing therapy.~8. Pregnant women or women of child bearing age not willing to commit to dual contraception prophylaxis~9. Use of alemtuzumab (Campath 1-H©), basilixumab (Simulect©) and daclizumab (Zenapax©) are not permitted in this protocol; Use of other immunosuppressive agents must be limited to those specified in this protocol.~10. Prisoners or subjects who are involuntarily incarcerated.~11. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.~12. Pre-sensitized patients with alloscreen antibody levels of 80% or more class I or class II

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Belatacept (Type: ACTIVE_COMPARATOR): Belatacept 10mg/kg administered intravenously on days 1, 4, 15, and 28, weeks 8 and 12. Then continue at 5mg/kg every 4 weeks throughout the completion of the study.
- Everolimus (Type: ACTIVE_COMPARATOR): Everolimus 1.5 mg/kg twice a day by mouth, the dose will be adjusted after Day 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy young controls who are 20 - 30 years old and have no subjective memrory complaints~* Cognitively normal elderly who have Clinical Dementia Rating score of 0~* Alzheimer's disease (AD) patients who met both the DSM-IV criteria for dementia and NINCDS-ADRDA criteria for probable AD~Exclusion Criteria:~* any present serious medical, psychiatric, or neurological disorder that could affect mental function; evidence of focal brain lesions on MRI; the presence of severe behavioral or communication problems

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- SNUBH-NM-333(18F), Safety, Efficacy (Type: EXPERIMENTAL): 10 young controls, 10 cognitively normal elderly, and 10 Alzheimer's disease patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
SELECTED INCLUSION CRITERIA:~1. Subjects must be competent to provide written informed consent;~2. Subjects must have completed the Maintenance Period of the DAR-312 study.~SELECTED EXCLUSION CRITERIA:~1. Subjects who discontinue treatment with study drug prior to the end of the Maintenance Period in DAR-312 due to a study drug-related AE;~2. Subjects who experience a study drug-related serious adverse event (SAE) during the DAR-312 study.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan (Type: EXPERIMENTAL): Darusentan capsules titrated to an optimal dose of 50 mg, 100 mg, or 300 mg administered orally once daily
- Guanfacine (Type: ACTIVE_COMPARATOR): Guanfacine 1 mg capsules administered orally once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older~* Willing to provide informed consent~* ECOG performance status 0-2~* Histologically confirmed non-small cell lung carcinoma~* Locally advanced stage IIIA or IIIB lung carcinoma according to AJCC 7th edition~* Expected lung V20 of 35-60%, as determined at the time of 4D-CT simulation~* Assessment by medical oncologist and radiation oncologist, with adequate hepatic and renal function for administration of cisplatin-based doublet chemotherapy, at the discretion of the medical oncologist~Exclusion Criteria:~* Serious medical comorbidities or other contraindications to radiotherapy or chemotherapy~* Prior history of lung cancer within 5 years~* Prior thoracic radiation at any time~* Metastatic disease~* in some select cases, patients with a solitary metastasis (i.e. brain metastasis) may receive radical chemoradiotherapy after resection/ablation of their metastatic lesion, as standard practice. In such cases, the patient may be enrolled onto this study at the discretion of the local principle investigator once the metastasis has been treated.~* inability to attend full course of radiotherapy of follow-up visits~* Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Shrinking Target Adaptive Radiotherapy (Type: EXPERIMENTAL): Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Multicentric Evaluation of a Bladder Preservation Strategy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* T2 clinical stage (no palpable mass under anesthesia after TURB) Absence of diffuse Cis (Cis on random bladder biopsies) Patients above 18, and below 70 years of age PS status ≤ 2 No previous treatment for a bladder muscle infiltrative carcinoma. Previous endovesical instillations for non muscle infiltrative lesions (pTa, pT1, Cis) are allowed.~No metastases on tauraco-abdomina-pelvic CT scan (no node \> 1 cm) and bone scan.~Normal biological values: neutrophils \> 1,5.109 /l, platelets \> 100. 109 /l, Alkaline Phosphatases \< 2 x N, bilirubin \< 1,5 N, Transaminases \< 1,5 x N, Creatinine clearance ≥ 60 ml/min Signed inform consent Patient belonging to a social security system.~Exclusion Criteria:~All other histology than urothelial carcinoma:~* primitive adenocarcinoma~* epidermoid carcinoma~* little cells carcinoma In situ diffuse carcinoma associated with urothelial carcinoma muscular infiltrating Tumor stade \> T2, T3 or T4 or pT4a (prostatitis) Serious cardiac, pulmonary, hepatitic, renal, digestive or neurological pathology which is non equilibrating or potential aggravating risk by treatment Cancer history or other actual cancer (except skin cancer) not remission or with an end of treatment inferior to 2 years Participation to another clinical trial in a delay inferior to 30 days

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- surgical resection and chemotherapy (Type: EXPERIMENTAL): Maximal and optimal TURB using a standardized procedure. The TURB will always try to be optically complete.~Neoadjuvant chemotherapy for 3 months with the intensified MVAC (6 cycles administered every 2 weeks): METHOREXATE: 30 mg/m2 D1 - VINBLASTINE: 3 mg/m2 D2 - ADRIAMYCINE 30 mg/m2 D2 - CISPLATINE 70 mg/m2 D2. + G-CSF: 5 µg/kg from D4 to D10 New maximal standardized TURB at the end of the chemotherapy. In case of a lesion localized at the bladder dome, and if a maximal TURB appears to be unsafe, a partial cystectomy without lymph node dissection will be performed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* pulmonary function: FEV1 \< 45 %, RV \> 150 %, TLC \> 100 %~* alpha1 antitrypsin deficiency (\< 80 mg/dl), genotype: PiZS, PiZZ, Pi0/0~* heterogenous emphysema~Exclusion Criteria:~* homogenous emphysema~* significant bronchiectasis~* severe concomitant diseases~* pregnancy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mometasone vs Budesonide in CRS With Polyposis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic rhinosinusitis with nasal polyps~* Absence of active infection at start of study~Exclusion Criteria:~* Diagnosis of chronic rhinosinusitis without nasal polyps~* Diagnosis of recurrent acute bacterial rhinosinusitis~* Previous sinus surgery (septal of inferior turbinate surgeries are not considered sinus surgeries)~* Cystic fibrosis or ciliary dyskinesia~* Allergy to corticosteroids~* Pregnant or lactating women~* Contra-indication to intranasal steroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mometasone nasal spray (Type: ACTIVE_COMPARATOR): Mometasone nasal spray 50 mcg/dose, 2 sprays/nostril twice daily x 3 months Patients will also be taking Sinus Rinse once daily throughout the study period
- Budesonide irrigation (Type: EXPERIMENTAL): 2 cc budesonide nebule (0,5 mg/cc) incorporated to 240 of saline water (Sinus Rinse) to be taken on a daily basis x 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be at least 18 years of age and competent to consent~* Patients must be diagnosed with resectable lung cancer or metastatic lung disease eligible to complete metastasectomy~* Patients must have one of: Male gender, age greater than 65, hypertension, obesity, and recent tobacco use within the past year~* Patients must be booked for pneumonectomy, lobectomy or anatomical segmentectomy resection.~Exclusion Criteria:~* Patients undergoing emergent lung resection~* Patients undergoing lung resection for non-oncologic indications (lung biopsy, bullectomy)~* Patients with an existing neurostimulator~* Patients with pre-existing cardiac disease, defined as:~  * Patients with atrioventricular blockage of any degree or sick sinus syndrome;~ * Patients with known previous atrial fibrillation or flutter lasting more than 1 month;~ * Patients with any persistent diagnosed preoperative arrhythmia~ * Patients with implanted external defibrillators or pacemakers~* Patients with known adhesive allergies~* Inability to comply with or understand ambulatory monitoring.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- iRhythm ZIO XT patch group (Type: EXPERIMENTAL): This is the only arm in the study and patients within it will have a small, pebble shaped device adhered to their chests. This is an ECG (electrocardiogram) monitor and will measure the incidence of atrial fibrillation. It will have to be worn for 14 days before and after the lung resection procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Phase II/III Study of Continuous Local Anesthetic Infusion in Median Sternotomy Following Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be greater than 18 years of age~2. Be undergoing a cardiac surgical procedure via median sternotomy (i.e., exclude the occasional thoracotomy, since much greater pain with that surgical approach post-operatively)~Exclusion Criteria:~1. Are unable to grant informed consent or comply with study procedure~2. Are undergoing emergency open heart-surgery~3. Allergic to any of the excipients in ropivacaine, propofol, and fentanyl~4. Age \< 18 years of age (children have dosing and toxicity concerns)~5. Are pregnant (pregnancy changes pain thresholds)~6. Taking preoperative opioids. (Opioid tolerant patients will require significantly more post-operative opioid use.)~7. Cirrhosis or hepatic failure (may have accumulation of local anesthetic in plasma due to decreased metabolism)~8. Patient receiving lidocaine infusion prior to surgery. (An extremely rare event)~9. Patients having a planned circulatory arrest for their surgical procedure (increased duration of intubation possible)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Ropivicaine infusion into the sternal wound
- 2 (Type: PLACEBO_COMPARATOR): Normal saline infusion into the sternal wound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Problematic alcohol use and having been recommended psychotherapy by the assessing psychologist.~Exclusion Criteria:~Inadequate Swedish language skills No Internet access Reading and/or writing difficulties Major depression Current suicidal thoughts and/or plans Primary problematic drug use PTSD-related problems Psychosis Cognitive disability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- eChange web-based relapse prevention (Type: EXPERIMENTAL): A relapse intervention program consisting of 14 modules. Patients will have access to therapist support through an internal secure messaging system.
- Face-to-face therapy (Type: ACTIVE_COMPARATOR): Face-to-face psychotherapy, consisting of 20 sessions. The content will be vary for different therapists, but all have an evidence-based approach to therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine in Untreated B-CLL Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Flow cytometry confirmed B-CLL~* No prior chemotherapy or immunotherapy~* Performance status 0-2~* Age \> 18 years old~* If childbearing age, woman you must be willing to use birth control for length of hydroxychloroquine use~* Must have capacity to consent for study and sign consent form~* Asymptomatic CLL not requiring treatment at time of study entry~Exclusion Criteria:~* Pregnancy~* Significant optic nerve pathology as documented by an opthalmologic exam~* Hypersensitivity to 4-aminoquinoline compound~* Patients taking cardiac glycosides and cyclosporine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine (Type: EXPERIMENTAL): Hydroxychloroquine 400 mg po daily for up to one year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Components of Metabolic Derangement and Paracentesis for Determination of Surgery in Preterm Neonates With Necrotizing Enterocolitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients equal to or less than 36.6 weeks gestation, with a diagnosis of NEC stage II A or greater according to Bell criteria.~Exclusion Criteria:~* Patients with a history of gastroschisis, suspected Hirschsprung's disease. Patients who do not give authorization for participation.~Elimination criteria:~Patients who during follow-up died due to some other condition. Patients who during the study declined to participate. Patients who in the surgical findings had data of Spontaneous Intestinal Perforation.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Components of metabolic derangement measurement every 3rd day, it was considered positive when 3 or more points were present. These patients underwent paracentesis and if it was positive (faecal aspiration, serous fluid with Gram + staining, or serohematic fluid) the decision for surgery was made.
- Control group (Type: ACTIVE_COMPARATOR): Determination of surgery in a conventional manner according to Bell's criteria (absolute indication: pneumoperitoneum), with radiographic surveillance every 6 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Unloading Respiratory Muscles During NIV: Comparison of a Spontaneous and Auto-adjusting Controlled Mode

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy voluntary individuals~* PFT within normal limits~Exclusion Criteria:~* Disease of the upper GI-tract~* Any form of lung disease or disease of the upper airways~* Any form of muscular disease, especially neuromuscular disease pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues